Textile wastewater treatment plant is re-equipped with X-Flow membranes
of 1
/1
Embed Size (px)
Transcript of Textile wastewater treatment plant is re-equipped with X-Flow membranes
NEWS
2Membrane Technology December 2012
Editorial Office: Elsevier Ltd The Boulevard, Langford Lane
Kidlington, Oxford OX5 1GB, UKFax: +44 (0)1865 843973
Web: www.membrane-technology.com
Publisher: David Hopwood
Editor: Simon AtkinsonTel/Fax: +44 (0)1904 655944
Email: [email protected]
Production Support Manager: Lin LucasE-mail: [email protected]
Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (HySA Infrastructure: NWU and CSIR),
Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A G Fane (University of New South Wales),
Dr A C M Franken (Membrane Application Centre Twente), Prof. E Gobina (Robert Gordon University),
Dr A Merry (Aquious–PCI Membranes), Prof. M Nyström (Lappeenranta University of Technology),
Dr Anil Pabby, Bhabha Atomic Research Centre, India Dr G K Pearce (Membrane Consultancy Associates),
Prof. P H Pfromm (Kansas State University), Dr R W Philpott (Progenta Llp),
Prof. R J Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Membrane Society)
Subscription InformationAn annual subscription to Membrane Technology includes 12 issues and online access for up to 5 users.Prices: �1273 for all European countries & Iran US$1427 for all countries except Europe and Japan ¥169 100 for Japan (Prices valid until 31 December 2012)To subscribe send payment to the address above. Tel: +44 (0)1865 843687 or via www.membrane-technology.com. Subscriptions run for 12 months, from the date payment is received.
Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments.Derivative WorksSubscribers may reproduce tables of contents or prepare lists of arti-cles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations.Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above.NoticeNo responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or oth-erwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advan ces in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
12978Digitally Produced by Mayfield Press (Oxford) Limited
Textile wastewater treatment plant is re-equipped with X-Flow membranes
Pentair X-Flow has re-equipped Go Go International Pvt Ltd’s textile
wastewater treatment plant, based in Hassan, Karnataka, India, with its Aquaflex 55 ultrafiltration (UF) mem-brane modules.
After the original membranes failed repeat-edly, the clothing manufacturer decided to change them and chose X-Flow’s Aquaflex 55 to achieve the designed water quality and quantity.
The membranes are used to provide opti-mum pretreatment for a reverse osmosis unit. According to Pentair X-Flow, they have out-standing anti-fouling properties and deliver consistent separation performance, with low energy consumption.
The use of Aquaflex 55 has lowered turbidity from 10 NTU to less than 0.1 NTU, says the company. Colour is removed and the designed permeate flow rate of 40 m3/h is achieved at a feed-pressure of 0.03 MPa (0.3 bar).
Go Go International uses the treated water as process water for textile dyeing purposes.
Contact:
X-Flow Bv, Marssteden 50, 7547 TC Enschede,
The Netherlands. Tel: +31 53 428 7350,
www.x-flow.com, www.cptholding.com
Filter combines cross-flow filtration with centrifugal separation
Dow Water & Process Solutions (DW & PS), a business unit of Dow
Chemical Co, has launched the Tequatic Plus fine particle filter, which has been developed for use in demanding water environments.
With its patented design, the filter combines the power of continuously cleaning, cross-flow filtration with centrifugal separation, in single device, which is specifically designed to handle difficult-to-treat feed-water more consistently and cost-effectively than traditional technolo-gies, says the company.
The filter is produced by Clean Filtration Technologies Llc (CFT), which became a wholly owned subsidiary of Dow in April 2012.
According to Cedella Beazley, General Manager, CFT, this filter represents a breakthrough in that it is able to tackle applications involving difficult-to-treat water – reliably handling high and highly variable total suspended solids (TSS).
‘Working together, CFT and Dow have accelerated technology development to an unprecedented level, resulting in an early mar-ket introduction of this exciting system,’ com-mented Beazley.
‘By adding the Tequatic Plus filter to its line-up, DW & PS can now meet needs for fine particle filtration, continuing its commitment to offering customers the most complete portfo-lio of advanced water purification technology.’
John Patrin, Strategic Marketing Manager, CFT, added: ‘It has the ability to filter water with high and variable solids with almost no maintenance, fouling and back-wash cycles, and there is no need for cartridge filters. This adds up to lower maintenance and consumables costs, and high uptime – all of which contrib-ute to a lower cost of ownership.’
Patrin also cites several environmental and safety advantages for customers looking to enhance the sustainability of their operations.
He said: ‘The Tequatic Plus filter requires minimal filter changes and chemicals, which minimises handling hazards and disposal, help-ing to reduce the impact on the environment.’
Applications include pretreatment for ultra-filtration and reverse osmosis, and filtration of produced water in the oil and gas sector. The product can be used as an alternative to (or a complement) traditional filtration technologies. It is currently available in various flow rates with filter cut-offs of 10–55 μm to meet specific cus-tomer needs.
‘Looking ahead, the CFT team already has in development the next generation of technology for the Tequatic Plus filter – with the goal of providing customers with a full suite of innova-tive particle filtration technologies for difficult-to-treat feed-water,’ concluded Beazley.
Contact:
The Dow Chemical Co, Dow Water & Process Solutions,
Customer Information Center, PO Box 1206, Midland,
MI 48642-1206, USA. Tel: +1 989 636 9086,
www.dowwaterandprocess.com, www.dow.com
Kits developed for quality control of in vitro stem cell cultures
EMD Millipore, the life science divi-sion of Germany’s Merck KgaA,
